Analyze the new anti-tumor drug Dayoutong?: Blocking blood vessel supply and "starving" the tumor

Source: China News Network

The anti-tumor drug DaYotong® was approved by the National Medical Products Administration (NMPA) of China, and its indications are advanced non-squamous non-small cell lung cancer and metastatic colorectal cancer.

Cinda Biopharmaceutical Group, the independent researcher of the drug, was informed of this news. Cinda Biotech stated that this is their second monoclonal antibody drug to be marketed after Daboshu® (sintilimab injection).

Analysis of the principle and mechanism: blocking the blood vessel supply and starving the tumor

According to reports, lung cancer is the first malignant tumor in China with the highest incidence and mortality, while the incidence and mortality of colorectal cancer rank third and fifth respectively.

"In layman's terms, this drug can block blood vessel supply, and ultimately "starve" the tumor in the body." The head of the Xinda Biological R&D team said that the principle and mechanism of Dayotong® anti-tumor is by blocking vascular endothelial growth factor. VEGF inhibits tumor angiogenesis, cuts off the blood supply to the tumor area, inhibits tumor growth and metastasis, induces tumor cell apoptosis, and achieves anti-tumor therapeutic effects.

The person in charge also said that Dayoto® can be combined with platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-squamous cell non-small cell lung cancer. It can also be combined with fluorine. Pyrimidine-based chemotherapy is used for the treatment of patients with metastatic colorectal cancer.

Drug development hot spots: immunotherapy and anti-angiogenesis therapy

Dr. Zhou Hui, vice president of Cinda Biomedical Science and Strategic Oncology Department, introduced that the combination of immunotherapy and anti-angiogenesis therapy has a synergistic effect on the mechanism of action, and is currently a hot spot in the clinical development of anti-tumor drugs.

Zhou Hui revealed that the results of their ongoing Phase Ib preliminary clinical trial of Dayoto® combined with Daboshu® in the treatment of advanced hepatocellular carcinoma will be announced at this year's ASCO annual meeting. "The data show that the combined use of these two drugs has achieved initial positive effects in patients with advanced hepatocellular carcinoma." He said.

He also said that Dayoto® is an anti-VEGF monoclonal antibody with international quality and has authorized its commercialization rights in the United States and Canada to the US pharmaceutical company Coherus, which means Cinda Bio's ability in the field of macromolecular drug research and development Obtained international recognition.

make patients affordable: two drugs are included in the national medical insurance list

High-quality biological drugs, in the final analysis, have to be affordable to the people. And this is also the "initial intention" of Cinda since its establishment.

In November 2019, Daboshu® became the only PD-1 inhibitor to enter the new version of the National Medical Insurance List. The annual treatment cost for patients is less than RMB 100,000, which is only one-twelfth of similar drugs in the United States. The reporter learned that Dayoton® will also be included in the national medical insurance catalog, making it available and affordable to the people.

Que Hong, senior vice president of Cinda Bio, emphasized that it took 8 years for Dayotong® to go on the market, and “through a lot of research, scientific and rigorous targets have been established.” She said that the industrialization base for producing the drug also complies with China's NMPA. GMP standards of the US FDA and European EMA. Clinical data shows that the drug has a good therapeutic effect on advanced non-small cell lung cancer and metastatic colorectal cancer.